Gunter von Minckwitz

Summary

Affiliation: German Breast Group
Country: Germany

Publications

  1. ncbi request reprint What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?
    Gunter von Minckwitz
    German Breast Group GBG Forschungs GmbH, Neu Isenburg, Germany
    Oncology (Williston Park) 26:20-6. 2012
  2. doi request reprint Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
    G von Minckwitz
    German Breast Group
    Ann Oncol 22:301-6. 2011
  3. doi request reprint Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    J Clin Oncol 29:2150-7. 2011
  4. doi request reprint Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)
    Gunter von Minckwitz
    German Breast Group, c o GBG Forschungs GmbH, Martin Behaim Straße 12, 63263 Neu Isenburg, Germany
    Breast Cancer Res Treat 132:863-70. 2012
  5. ncbi request reprint Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany Universität Frankfurt, Frauenklinik, Frankfurt, Germany Electronic address
    Lancet Oncol 15:747-56. 2014
  6. ncbi request reprint Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany Univ Women s Hospital, Frankfurt, Germany Senologic Oncology, Dusseldorf, Germany Electronic address
    Breast 22:S149-51. 2013
  7. doi request reprint Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    Clin Cancer Res 19:4521-31. 2013
  8. doi request reprint Neoadjuvant therapy: what are the lessons so far?
    Gunter von Minckwitz
    German Breast Group, Martin Behaim Str 12, Neu Isenburg 63263, Germany
    Hematol Oncol Clin North Am 27:767-84, ix. 2013
  9. doi request reprint Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    Curr Opin Obstet Gynecol 25:66-73. 2013
  10. doi request reprint Optimizing taxane use in MBC in the emerging era of targeted chemotherapy
    G von Minckwitz
    German Breast Group, Neu Isenburg and Universitäts Frauenklinik Frankfurt, Germany
    Crit Rev Oncol Hematol 85:315-31. 2013

Detail Information

Publications59

  1. ncbi request reprint What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?
    Gunter von Minckwitz
    German Breast Group GBG Forschungs GmbH, Neu Isenburg, Germany
    Oncology (Williston Park) 26:20-6. 2012
    ..Recent findings suggest pCR might not be the appropriate surrogate for long-term outcome in patients with hormone receptor-positive and HER2-positive tumors...
  2. doi request reprint Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
    G von Minckwitz
    German Breast Group
    Ann Oncol 22:301-6. 2011
    ..Safety data for combining bevacizumab, everolimus, or lapatinib with anthracycline- and taxane-based neoadjuvant chemotherapy for breast cancer are limited...
  3. doi request reprint Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    J Clin Oncol 29:2150-7. 2011
    ..Poly(adenosine diphosphate-ribose) polymerase (PARP) plays a key role in DNA repair and cellular stress response. Inhibitors of PARP show promising clinical activity in metastatic, triple-negative or BRCA-mutated breast cancer...
  4. doi request reprint Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)
    Gunter von Minckwitz
    German Breast Group, c o GBG Forschungs GmbH, Martin Behaim Straße 12, 63263 Neu Isenburg, Germany
    Breast Cancer Res Treat 132:863-70. 2012
    ..However, complete eradication of adjacent DCIS is frequently observed. HER2-overexpression of the invasive ductal component decreases in a subset of tumors, which showed less tumor regression...
  5. ncbi request reprint Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany Universität Frankfurt, Frauenklinik, Frankfurt, Germany Electronic address
    Lancet Oncol 15:747-56. 2014
    ..We therefore aimed to assess the efficacy of the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive breast cancer...
  6. ncbi request reprint Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany Univ Women s Hospital, Frankfurt, Germany Senologic Oncology, Dusseldorf, Germany Electronic address
    Breast 22:S149-51. 2013
    ..However, as shown in GaparQuinto and NSABP 40 trials, treatment effect in TNBC might be further maximized by adding bevacizumab, and two randomized neoadjuvant trials are expected this year to report data on the efficacy of carboplatin. ..
  7. doi request reprint Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    Clin Cancer Res 19:4521-31. 2013
    ..The value of Ki67 measured on residual disease after neoadjuvant chemotherapy is not sufficiently described...
  8. doi request reprint Neoadjuvant therapy: what are the lessons so far?
    Gunter von Minckwitz
    German Breast Group, Martin Behaim Str 12, Neu Isenburg 63263, Germany
    Hematol Oncol Clin North Am 27:767-84, ix. 2013
    ....
  9. doi request reprint Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    Curr Opin Obstet Gynecol 25:66-73. 2013
    ..Neoadjuvant treatment is used by an increased number of patients with breast cancer. This study reviews the current literature on how new research findings have impacted patients and treatment selection...
  10. doi request reprint Optimizing taxane use in MBC in the emerging era of targeted chemotherapy
    G von Minckwitz
    German Breast Group, Neu Isenburg and Universitäts Frauenklinik Frankfurt, Germany
    Crit Rev Oncol Hematol 85:315-31. 2013
    ....
  11. ncbi request reprint Neoadjuvant treatments for triple-negative breast cancer (TNBC)
    G von Minckwitz
    German Breast Group, GBG Forschungs GmbH, Neu Isenburg, Germany
    Ann Oncol 23:vi35-9. 2012
    ..The use of neoadjuvant treatment with pCR as a surrogate of overall survival will allow the rapid evaluation and comparison of these and other much-needed new treatments for TNBC...
  12. doi request reprint Neoadjuvant chemotherapy in breast cancer-insights from the German experience
    Gunter von Minckwitz
    German Breast Group, GBG Forschungs GmbH, Martin Beheim Str 12, 63263, Neu Isenburg, Germany
    Breast Cancer 19:282-8. 2012
    ..Strategies are currently being developed on how locoregional treatment can be reduced in patients with a pathological complete response. These aim to reduce the extent of surgery or even avoid surgery completely...
  13. doi request reprint Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
    Gunter von Minckwitz
    German Breast Group, c o GBG Forschungs GmbH, Martin Behaim Straße 12, 63263 Neu Isenburg, Germany
    J Clin Oncol 30:1796-804. 2012
    ..The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain...
  14. pmc Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel
    Eva J Kantelhardt
    Klinik und Poliklinik für Gynäkologie, Martin Luther Universitat, Halle Saale, Germany
    BMC Cancer 11:140. 2011
    ..High-risk node-negative patients should receive chemotherapy. Anthracycline-based regimens are accepted as a standard, the additional benefit of taxanes remains an open question...
  15. doi request reprint The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, Germany
    Cancer Epidemiol Biomarkers Prev 20:2141-9. 2011
    ..Today, premenopausal women with increased risk for breast cancer have only limited nonsurgical options to reduce their risk...
  16. doi request reprint Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
    Gunter von Minckwitz
    German Breast Group, GBG ForschungsGmbH, Martin Behaim Str 12, 63263 Neu Isenburg, Germany
    Eur J Cancer 47:2273-81. 2011
    ..Here, we report the final analysis on overall survival...
  17. doi request reprint Lessons from the neoadjuvant setting on how best to choose adjuvant therapies
    Gunter von Minckwitz
    German Breast Group, Neu Isenhurg and Senologic Oncology, Luisenkrankenhaus Diisseldorf, Isenburg, Germany
    Breast 20:S142-5. 2011
    ..To review the recent literature on neoadjuvant treatment of breast cancer with respect to insights that might be used for better using systemic treatment in early breast cancer...
  18. doi request reprint Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
    Gunter von Minckwitz
    German Breast Group, c o GBG Forschungs GmbH, Martin Behaim Str 12, 63263 Neu Isenburg, Germany
    Breast Cancer Res Treat 125:145-56. 2011
    ....
  19. doi request reprint Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
    Gunter von Minckwitz
    Universitäts Frauenklinik Frankfurt, German Breast Group Forschungs GmbH, Martin Behaim Strasse 12, 63263 Neu Isenburg, Germany
    J Clin Oncol 28:2015-23. 2010
    ..CONCLUSION Adding capecitabine to or prolonging duration of neoadjuvant EC plus docetaxel does not result in higher efficacy at surgery...
  20. doi request reprint Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study
    Gunter von Minckwitz
    GBG Forschungs GmbH, University of Frankfurt, Schleussnerstr 42, Neu Isenburg, Germany 63263
    J Clin Oncol 27:1999-2006. 2009
    ..In the German Breast Group 26/Breast International Group 03-05 trial, we investigated if trastuzumab treatment should be continued beyond progression...
  21. doi request reprint Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
    Gunter von Minckwitz
    Headquarters, German Breast Group, Neu Isenburg, Germany
    N Engl J Med 366:299-309. 2012
    ....
  22. pmc Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
    Gunter von Minckwitz
    Dept of Gynecology and Obstetrics, Goethe University, Frankfurt am Main, Germany
    Breast Cancer Res 10:R30. 2008
    ..To investigate the predictive value of clinical and biological markers for a pathological complete remission after a preoperative dose-dense regimen of doxorubicin and docetaxel, with or without tamoxifen, in primary operable breast cancer...
  23. doi request reprint Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
    Gunter von Minckwitz
    German Breast Group, Frankfurt, Germany
    J Natl Cancer Inst 100:542-51. 2008
    ..We compared the response of nonresponding patients who continued the same treatment with that of patients who switched to a well-tolerated non-cross-resistant regimen...
  24. doi request reprint Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
    Michael Untch
    Universitäts Frauenklinik Frankfurt, c o GBG Forschungs GmbH, Martin Behaim Str 12, 63263 Neu Isenburg, Germany
    J Clin Oncol 28:2024-31. 2010
    ..Combination of chemotherapy with trastuzumab should be considered when neoadjuvant treatment is given to patients with HER2-positive breast cancer...
  25. doi request reprint Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
    Gunter von Minckwitz
    German Breast Group, Frankfurt, Germany
    J Natl Cancer Inst 100:552-62. 2008
    ..The relationship between extended chemotherapy and pathological complete response at surgery was investigated in a clinical trial...
  26. doi request reprint German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
    Gunter von Minckwitz
    Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu Isenburg Volker Möbus, Klinikum Frankfurt Hoechst, Frankfurt Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg Jens Huober, University Hospital Dusseldorf, Düsseldorf Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale Michael Untch, Helios Klinikum Berlin Buch, Berlin Christian Jackisch, Klinikum Offenbach, Offenbach Ingo J Diel, Schwerpunktpraxis für gynäkologische Onkologie, Mannheim Dirk Elling, Sana Klinikum Lichtenberg, Lichtenberg Bettina Conrad, Frauenklinik, Kassel Rolf Kreienberg, University Hospital Ulm, Ulm Volkmar Müller, University Hospital Hamburg, Hamburg Hans Joachim Lück, Praxis Hannover Stefanie Noeding, Nordstadt Krankenhaus, Hannover Ingo Bauerfeind, Frauenklinik Landshut, Landshut Michael Clemens, Klinikum Trier
    J Clin Oncol 31:3531-9. 2013
    ..Their effect in early breast cancer is controversial. Ibandronate is an orally and intravenously available amino-bisphosphonate with a favorable toxicity profile. It therefore qualifies as potential agent for adjuvant use...
  27. ncbi request reprint CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93)
    Gunter von Minckwitz
    German Breast Group, Schleussnerstrase 42, 63263 Neu Isenburg, Germany
    Eur J Cancer 42:1780-8. 2006
    ..79 (95% CI=0.54-1.14; P=0.19). It is concluded that medical ovarian ablation with goserelin represents a valid option for premenopausal patients with node-negative breast cancer...
  28. pmc Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
    Sibylle Loibl
    Department of Obstetrics and Gynecology, German Breast Group, Neu Isenburg, Germany
    Breast Cancer Res 10:R77. 2008
    ..Furthermore, most physicians tend towards therapy regimens without the use of dose-dense, highly active taxane-based treatments because of a lack of data regarding toxicities of these compounds in older patients...
  29. ncbi request reprint Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial
    Sibylle Loibl
    Department of Obstetrics and Gynecology, J W Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    Ann Surg Oncol 13:1434-42. 2006
    ..Neoadjuvant chemotherapy can increase the rate of breast-conserving surgery in patients with operable breast cancer. However, uncertainty remains regarding surgical procedures and predictors for successful breast-conserving surgery...
  30. doi request reprint Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
    Volker Moebus
    Department of Gynecology and Obstetrics, Klinikum Frankfurt Hoechst, Academic Hospital of Goethe University Frankfurt, Gotenstrasse 6 8, D 65929, Frankfurt, Germany
    J Clin Oncol 28:2874-80. 2010
    ..We compared intense dose-dense (IDD) adjuvant chemotherapy with conventionally scheduled adjuvant chemotherapy in patients with high-risk primary breast cancer...
  31. doi request reprint Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
    Sibylle Loibl
    German Breast Group, Martin Behaim Str 12, 63263 Neu Isenburg, Germany
    Breast Cancer Res Treat 130:477-87. 2011
    ..Patients with an AR-negative tumour have a higher chance of achieving a pCR than those with an AR-positive one. But, patients with AR-positive tumours have a better survival especially if they did not achieve a pCR...
  32. ncbi request reprint Response-guided neoadjuvant chemotherapy for breast cancer
    Gunter von Minckwitz
    Gunter von Minckwitz, Keyur Mehta, and Sibylle Loibl, Headquarters, German Breast Group, Neu Isenburg Jens Uwe Blohmer, St Gertrauden Krankenhaus, Berlin Serban Dan Costa, Universitats Frauenklinik, Magdeburg Carsten Denkert, Institute for Pathology, Charite, Berlin Holger Eidtmann, Universitäts Frauenklink, Kiel Wolfgang Eiermann and Claus Hanusch, Klinikum zum Roten Kreuz, Munich Bernd Gerber, Universitats Frauenklinik, Rostock Jörn Hilfrich, Henrietten Stiftung, Hanover Jens Huober, Universitats Frauenklinik Tubingen, Frauenklinik Christian Jakisch and Sibylle Loibl, Städtische Kliniken, Offenbach Gunter von Minckwitz, Universitats Frauenklinik, Frankfurt Sherko Kümmel, Klinikum Essen Mitte, Essen Stefan Paepke, Universitäts Frauenklinik rechts der Isar, Munich Andreas Schneeweiss, National Center for Tumor Diseases, Turkey
    J Clin Oncol 31:3623-30. 2013
    ..We investigated disease-free survival (DFS) and overall survival (OS) after response-guided neoadjuvant chemotherapy in patients with early breast cancer...
  33. doi request reprint Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    Support Care Cancer 19:1789-95. 2011
    ..Preliminary data suggest that pegfilgrastim given on day 4 (P4) might be superior to pegfilgrastim on day 2 (P2) in reducing grade 4 leucopenia...
  34. ncbi request reprint Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer
    Eugen Ruckhäberle
    Department of Gynecology, J W Goethe University, 60590, Frankfurt, Germany
    Breast Cancer Res Treat 112:41-52. 2008
    ..Targeting of the sphingolipid rheostat may thus open new treatment options...
  35. ncbi request reprint Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group
    Manfred Kaufmann
    Universitats Frauenklinik, Frankfurt, Germany
    J Clin Oncol 23:7842-8. 2005
    ..To investigate the effect of adjuvant sequential tamoxifen after chemotherapy in postmenopausal patients with hormone receptor-negative breast cancer...
  36. ncbi request reprint Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
    Manfred Kaufmann
    Department of Obstetrics and Gynecology, J W Goethe University Hospital, Frankfurt, Germany
    J Clin Oncol 24:1940-9. 2006
    ..As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined...
  37. ncbi request reprint Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg Frankfurt, Germany
    J Clin Oncol 23:2676-85. 2005
    ..Dose-dense and sequential administration of cytotoxic drugs are current approaches to improve outcomes in patients with early-stage breast cancer...
  38. ncbi request reprint Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study
    Manfred Kaufmann
    Department of Obstetrics and Gynaecology, J W Goethe University of Frankfurt, Frankfurt am Main, Frankfurt Main, Germany
    J Clin Oncol 25:2664-70. 2007
    ..This report presents results of a prospective, open-label, randomized study, designed to evaluate the benefits of switching to anastrozole after 2 years of tamoxifen treatment, compared with continuing on tamoxifen for 5 years...
  39. pmc Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    BMC Cancer 11:131. 2011
    ..Chemotherapy dose delay and/or reduction lower relative total dose intensity (RTDI) and may affect short- and long-term outcome of metastatic breast cancer (MBC) patients...
  40. doi request reprint Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer
    Manfred Kaufmann
    Department of Gynecology and Obstetrics and Breast Unit, Goethe University, Frankfurt, Germany
    Ann Surg Oncol 19:1508-16. 2012
    ..The obtained consensus was updated in two subsequent meetings in 2004 and 2006. The most recent conference on recommendations on the use of NST took place in 2010 and forms the basis of this report...
  41. ncbi request reprint International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations
    Manfred Kaufmann
    Department of Gynecology and Obstetrics, Goethe University, Frankfurt am Main, Germany
    J Clin Oncol 21:2600-8. 2003
    ..Recommendations are made regarding terminology, indications, regimen, diagnosis before treatment, monitoring of efficacy, tumor localization, surgery, pathologic evaluation, and postoperative treatment...
  42. doi request reprint Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial
    Sibylle Loibl
    German Breast Group, GBG Forschungs GmbH, Schleussnerstrasse 42, 63263, Neu Isenburg, Germany
    Cancer Chemother Pharmacol 63:953-8. 2009
    ..The aim of the RiTa trial is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule in anthracycline pre-treated metastatic breast cancer patients...
  43. doi request reprint Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
    Sibylle Loibl
    German Breast Group, GBG Forschungs GmbH, Martin Behaim Strasse 12, 63263, Neu Isenburg, Germany
    Breast Cancer Res Treat 144:153-62. 2014
    ..The mastectomy rate was considerably high in ILC patients even after obtaining a pCR. We, therefore, suggest to offer NACT mainly to ILC patients with HR-negative tumours...
  44. doi request reprint Treatment of breast cancer during pregnancy: an observational study
    Sibylle Loibl
    German Breast Group, Neu Isenburg, Germany
    Lancet Oncol 13:887-96. 2012
    ..Little is known about the treatment of breast cancer during pregnancy. We aimed to determine whether treatment for breast cancer during pregnancy is safe for both mother and child...
  45. ncbi request reprint Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS
    Sibylle Loibl
    Department of Gynecology and Obstetrics, University of Frankfurt, Theodor Stern Kai 7 9, 60590 Frankfurt am Main, Germany
    Pathol Res Pract 202:1-7. 2006
    ..In conclusion, e-NOS and i-NOS are weakly expressed in the MCF-7 cell line, but are stimulated differently. The MCF-7 cell may contain both a constitutive NOS and an inducible NOS...
  46. ncbi request reprint Preoperative (neoadjuvant) systemic treatment of breast cancer
    Manfred Kaufmann
    Department of Obstetrics and Gynaecology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Breast 14:576-81. 2005
    ..PST will lead to individualised (tailored) treatment in patients with primary breast cancer...
  47. doi request reprint [High-risk situation - which is the best chemotherapy?]
    Gunter von Minckwitz
    German Breast Group, Neu Isenburg, und Zentrum fur Frauenheilkunde und Geburtshilfe, Johann Wolfgang Goethe Universitat Frankfurt, Frankfurt, Deutschland
    Gynakol Geburtshilfliche Rundsch 48:118-29. 2008
    ....
  48. ncbi request reprint Breast carcinoma during pregnancy. International recommendations from an expert meeting
    Sibylle Loibl
    Department of Obstetrics and Gynaecology, J W Goethe University, Frankfurt am Main, Germany
    Cancer 106:237-46. 2006
    ..Breast carcinoma during pregnancy (BCP) is a difficult clinical situation, as it appears to put the health of the mother in conflict with that of the fetus...
  49. pmc Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial
    Yasmin Issa-Nummer
    German Breast Group, Neu Isenburg, Germany
    PLoS ONE 8:e79775. 2013
    ..The aim of this study was to prospectively validate the tumor-associated lymphocyte infiltrate as predictive marker for response to anthracycline/taxane-based NACT...
  50. ncbi request reprint Docetaxel/anthracycline combinations for breast cancer treatment
    Gunter von Minckwitz
    German Breast Group, Univ Women s Hospital Frankfurt, Schleussnerstr 42, 63263 Neu Isenburg, Germany
    Expert Opin Pharmacother 8:485-95. 2007
    ..However, when used as primary prophylaxis with granulocyte growth factors, as well as antibiotics, this regimen is considered as a safely-applicable standard option for early breast cancer treatment...
  51. ncbi request reprint Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy
    Sibylle Loibl
    Department of Gynecology and Obstetrics, University of Frankfurt, Frankfurt am Main, Germany
    Cancer 95:1191-8. 2002
    ..An increased NO concentration catalyzed by NO synthase (NOS) is cytotoxic and can promote apoptosis. The expression of endothelial NOS (e-NOS) and induced NOS (i-NOS) was examined in various breast tumors...
  52. doi request reprint Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel
    Manfred Kaufmann
    Department of Gynecology and Obstetrics, Goethe University, Frankfurt am Main, Germany
    Cancer 116:1184-91. 2010
    ....
  53. ncbi request reprint A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
    Gunter von Minckwitz
    German Breast Group Universitäts Frauenklinik Frankfurt and Klinikum der Goethe Universitaet, Zentrum für Frauenheilkunde and Geburtshilfe, Neu Isenburg Frankfurt, Germany
    Breast Cancer Res Treat 89:165-72. 2005
    ..The clinical benefit and safety of the EGFR tyrosine kinase inhibitor gefitinib ('Iressa')1 was evaluated in this Phase II, multicentre study of patients with taxane and anthracycline pretreated, metastatic breast cancer...
  54. doi request reprint Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study
    Bernd Gerber
    University of Rostock, Rostock, Germany
    J Clin Oncol 29:2334-41. 2011
    ..We aimed to test the efficacy of ovarian function preservation with the LHRHa goserelin in patients with breast cancer...
  55. doi request reprint Breakthrough for neoadjuvant chemotherapy
    Gunter von Minckwitz
    German Breast Group and Universitäts Frauenklinik, Frankfurt, Germany
    Breast Cancer 15:27-30. 2008
    ....
  56. doi request reprint Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades
    Manfred Kaufmann
    Department of Obstetrics and Gynaecology, J W Goethe University, Frankfurt, Germany
    Arch Gynecol Obstet 288:1203-12. 2013
    ..Evidence-based medicine has helped to improve and standardise treatment of breast cancer. This review summarises the 10th Biedenkopf meeting that was held to review the advances in breast cancer understanding and treatment. ..
  57. ncbi request reprint Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1
    Achim Rody
    Department of Obstetrics and Gynecology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Clin Cancer Res 13:1115-22. 2007
    ..One of those genes is plexin B1, a cell-surface receptor for the semaphorin Sema4D (CD 100). However, the biological role of plexin B1 in breast cancer is largely unknown...
  58. ncbi request reprint Evidence-based treatment of metastatic breast cancer - 2006 recommendations by the AGO Breast Commission
    Gunter von Minckwitz
    Spokesman of the AGO Breast Commission, Univ Women s Hospital Frankfurt, German Breast Group, Schleussnerstr 42, 63263 Neu Isenburg, Germany
    Eur J Cancer 42:2897-908. 2006
    ..In the following, an overview is given on the most important aspects in diagnosis and therapy of metastatic breast cancer. For detailed aspects, a comprehensive set of slides including a more complete bibliography may be accessed under ...
  59. doi request reprint Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
    Serban Dan Costa
    Universitats Frauenklinik, Magdeburg, German
    J Clin Oncol 28:83-91. 2010
    ..51; 95% CI, 0.88 to 2.59; P = .13). CONCLUSION No evidence of a difference in response to neoadjuvant chemotherapy was found by tumor stage when analysis was adjusted for baseline characteristics...